Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

15.87
-0.5500-3.35%
Post-market: 15.86-0.0100-0.06%18:12 EDT
Volume:3.44M
Turnover:54.76M
Market Cap:1.88B
PE:-13.71
High:16.35
Open:16.24
Low:15.45
Close:16.42
Loading ...

Company Profile

Company Name:
Arcutis Biotherapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
342
Office Location:
3027 Townsgate Road,Suite 300,Westlake Village,California,United States
Zip Code:
91361
Fax:
- -
Introduction:
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Directors

Name
Position
Patrick J. Heron
Chairman, Director
Todd Franklin Watanabe
Director, President and Chief Executive Officer
Alexander G. Asam
Director
Bhaskar Chaudhuri
Director
Daniel J. Estes
Director
Jonathan T. Silverstein
Director
Joseph L. Turner
Director
Ricky Sun
Director

Shareholders

Name
Position
Todd Franklin Watanabe
Director, President and Chief Executive Officer
John W. Smither
Chief Financial Officer
Patricia A. Turney
Senior Vice President, Manufacturing
Charlotte Merritt
Vice President, Regulatory Affairs
David Berk
Vice President, Clinical Development
David W. Osborne
Chief Technical Officer
Frank Pompilio
Vice President, Medical Affairs
Howard G. Welgus
Chief Medical Officer
Keith L. Klein
General Counsel
Kenneth A. Lock
Chief Commercial Officer
Lynn Navale
Vice President, Biometrics
Meg Elias
Vice President, Clinical Operations
Scott L. Burrows
Vice President, Finance